key: cord-0775169-ntbgyuka authors: Chan, Marina; Vijay, Siddharth; McElrath, M. Juliana; Holland, Eric C.; Gujral, Taranjit S title: Machine Learning Identifies Ponatinib as a Potent Inhibitor of SARS-CoV2-induced Cytokine Storm date: 2021-04-08 journal: bioRxiv DOI: 10.1101/2021.04.07.438871 sha: 51a2aabab019aa8bb6f830d71bb91b1597329a09 doc_id: 775169 cord_uid: ntbgyuka Although 15-20% of COVID-19 patients experience hyper-inflammation induced by massive cytokine production, cellular triggers of this process and strategies to target them remain poorly understood. Here, we show that the N-terminal domain (NTD) of the spike protein from the SARS-CoV-2 and emerging variants B1.1.7 and B.1.351 substantially induces multiple inflammatory molecules in human monocytes and PBMCs. Further, we identified several protein kinases, including JAK1, EPHA7, IRAK1, MAPK12, and MAP3K8, as essential downstream mediators of NTD-induced cytokine release. Additionally, we found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the NTD-mediated cytokine storm. Taken together, we propose that agents targeting multiple kinases required for the SARS-CoV-2-mediated cytokine storm, such as Ponatinib, may represent an attractive therapeutic option for treating moderate to severe COVID-19. spike protein causes massive upregulation of IL-1b in a dose-dependent manner (Fig. S1) . Next, we asked if S1 protein could promote upregulated expression of cytokines observed to be elevated in COVID-19 patients. Our data show that S1 protein stimulation (1g/mL) causes a significant increase in the expression of a panel of cytokines including IL-8 (~96-fold), IL-6 (5-fold), IL1b (~120-fold), TNF (~15-fold), and chemokines including CXCL10 (600-fold), CCL2 (~70-fold), CCL7 (4-fold) in THP1 monocytes (Fig. 1B) . Similar changes in cytokines were also observed in healthy donor PBMCs and Raw264.7 mouse monocytes in response to full-length S1 protein (Fig. S1 ). Together, these data indicate that interaction between Spike subunit S1 protein and monocytes is sufficient to activate monocytes. Next, we sought to determine the region of the S1 subunit that mediates monocyte activation. It has been established that SARS-CoV-2 and SARS-CoV recognize the angiotensinconverting enzyme 2 (ACE2) receptor in humans (4) . Specifically, the receptor-binding domain (RBD) of the spike subunit S1 protein of SARS-CoV-2 binds to ACE2 (4), thereby promoting the entry of the virus into the cells while the function of the N-terminal domain (NTD) is not well understood. Surprisingly, we found that stimulation with the HEK293 cells-produced NTD (Val 16 -Ser 305 ) of the S1 subunit is sufficient to promote cytokine expression while stimulation with the RBD (Arg 319 -Phe 541 ) of S1 protein could not activate THP1 monocytes (Fig. 1C) . Similar changes in the release of cytokines in the conditioned media were also observed in PBMCs from 20 healthy individuals in response to stimulation with NTD of S1 subunit (Fig. 1D) . Consistently, treatment with CV30(5) (high potent antibody targeting RBD of SARS-CoV-2) did not change S1 proteininduced expression of cytokines in PBMCs (Fig. 1E) . Further, stimulation with spike protein from two different endemic coronaviruses (HCoV-COV-2 and HCoV-OC43) did not promote cytokine release in THP1 cells (Fig.S1) , suggesting that the S1 subunit of SARS-CoV-2 contains a unique feature of this specific spike protein sequence required for monocytes activation. Together, these data suggest that NTD of S1 subunit interacts with a different receptor than ACE2, on monocytes to activate the 'cytokine storm.' To identify signaling pathways activated in monocytes in response to S1 spike protein and explore potential targets for therapeutic development, we employed a recently developed strategy that combines phenotypic screening with machine learning-based functional screening approaches, called KiDNN (6) and KiR (7, 8) . These strategies utilize large-scale drug-target profiling efforts, Regularized regression or Deep Neural Networks (DNN), and broadly selective chemical tool compounds to pinpoint specific nodes (kinases and associated networks) underlying a given phenotype, such as cell growth or release of secreted factors, e.g., cytokines ( Fig. 2A) . We screened a set of 35 computationally-chosen kinase inhibitors (7) and quantified their effect on changes in NTD-mediated release of seven cytokines in the conditioned media from pooled PBMCs (Fig. 2B, Dataset 1) . Using this training dataset, we built both elastic net regularization ( Fig. S2 ) and preliminary DNN models (Fig. S3) to predict kinases essential for the NTD-mediated release of cytokines. Using a multi-phase grid search, we optimized the hyperparameters for each preliminary DNN model (Fig. S3) . Model performance was evaluated using leave one out crossvalidation (LOOCV) mean squared error (MSE) between predicted and observed drug response. In LOOCV, each time 34 drugs' activity profiles were used to train the model to predict the remaining drug's effect on NTD-mediated cytokine release. MSE between predicted and observed cytokine levels was used to assign an error score to each model. Overall, models for each of the cytokines performed with at least 85% accuracy (Fig. S2) . The optimized models with the least mean squared errors collectively identified 30 most "informative kinases" (out of >300 kinases) that may be involved in the NTD-mediated cytokine release (Fig. S4) . These include several kinases known to play a critical role in cytokine signaling, such as JAK1 and IRAK1, as well as kinases not previously known to play a role in this process, like EPHA7, MAP3K8, and MAP3K2. Overall, MAP3K8 was shown to be enriched in the cytokine-mediated signaling network of all seven cytokines, while EPHA7 was enriched in networks of 4 out of 7 cytokines (Fig. S4) . Therefore, based on this analysis, we predicted that both MAP3K8 and EPHA7 are essential for the NTD-mediated release of cytokines. To validate the role of the kinases that we predicted to be important in cytokine signaling, we examined the effects of depleting these kinases in gene knockdown experiments. Using a pooled set of four siRNA, we knocked down the expression of top 13 kinases implicated by our KiDNN and KiR analyses (Fig. S4) in THP1 cells and measured their effect on NTD-mediated cytokine release. Transient transfections of pooled siRNA led to a 35-80% knockdown of each of the kinases measured by quantitative PCR (Fig. S4) . Our data showed that knockdown of 11 out of 13 kinases led to an >1.5-fold decrease in NTD-mediated cytokine levels compared with scrambled siRNA control (Fig. 2C ). Of these, knockdown of MAPK12, EPHA7, MAP3K8, PRKACG, IRAK1, MAP3K3, and JAK1 led to a decrease in more than one cytokine or chemokine ( Fig. 2C) . Network analysis based on prior information showed that several of these kinases are known to regulate common transcription factors such as MYC and REL (Fig. S4) . Together, these data confirmed KiR and KiDNN models' predictions and validated the role of at least seven kinases in the SARS-CoV2 S1 subunit NTD-mediated cytokine storm. Given that our analysis implicated multiple kinases that affect different signaling pathways in cytokine storm triggering, we hypothesized that a rational drug combination or multi-targeted therapy may represent an effective approach to blocking the SARS-CoV-2 mediated cytokine storm. Therefore, by taking advantage of non-linearity of DNN models and cloud computing, we predicted responses to 91 thousand two-drug combinations, as well as responses to 13 million combinations involving three-drug cocktails. Next, we used the optimized KiDNN models to predict both pairwise and single-agent responses to 427 single inhibitors that reduce NTDmediated cytokine levels (Fig. 3A) . In our analysis, we prioritized those compounds that are FDAapproved for human use, known to exhibit a low toxicity profile, and predicted to inhibit the release of multiple cytokines. Combinations containing the most promiscuous drugs, such as staurosporine and K252a, were excluded from this analysis. Our model indicated several FDA-approved compounds, including Ponatinib, Baricitinib, and Combimetinib, could inhibit NTD-mediated cytokine storm to varying levels as a single agent (Dataset 1). Of these, Ponatinib, an FDAapproved drug for chronic myelogenous leukemia, was predicted to be the most effective in blocking all seven cytokines as a single agent, as well as in combination (top 360 out of 500 combinations). We experimentally confirmed that treatment with Ponatinib potently inhibits NTDmediated cytokine release in PBMCs in a dose-dependent manner (EC50 10-28nM) (Fig. 3B, S5) . No significant changes in the viability of PBMCs were observed, even 1uM Ponatinib treatment (Dataset 1). Further, treatment with Ponatinib outperforms Baricitinib, a JAK inhibitor FDAapproved for the treatment of COVID-19 (9), in inhibiting all seven cytokines in response to NTD in PBMCs (Fig. S5) . Kinase activity profiling of Ponatinib showed that this drug inhibits 8 out of 10 experimentally-validated kinases necessary for the NTD-mediated cytokine and chemokine release (Fig. 3C, D) . In contrast, Baricitinib was shown to inhibit only 4 of these essential kinases. Thus, our data indicate that Ponatinib, a multi-specific kinase inhibitor, blocks the activity of several kinases that are essential for cytokine signaling thereby dampening the NTD-mediated cytokine storm. Recently, several new variants of SARS-CoV-2 have emerged, including the B.1.1.7 first identified in the United Kingdom and B.1.351 identified in South Africa that harbor mutation sites in the NTD. We asked if these variants could also promote cytokine release. We show that both B1.1.7 and B.1.351 NTDs could promote the release of cytokines in PBMCs at the levels comparable with the NTD from Wuhan SARS-CoV-2 (Fig. 4A) . Notably, Ponatinib treatment could inhibit the NTD-mediated release of cytokines from all variants. Further, Ponatinib treatment outperforms both dexamethasone and Baricitinib to block the cytokine release at the same dose ( Fig. 4A) . Finally, we evaluated the response of Ponatinib in PBMCs from 19 COVID19 patients. Our data show that NTD stimulation (1g/mL) causes a significant increase in the release of all seven cytokines measured in the conditioned media from COVID19 PBMCs (Fig. 4B) . Interestingly, all cytokines and chemokines showed a large variable response to NTD, suggesting an inherent patient-to-patient variability. However, treatment with 1uM Ponatinib completely shuts down NTD-mediated cytokine storm in all COVID-19 PBMCs. In contrast, 1uM dexamethasone, a corticosteroid prescribed to COVID-19 patients, showed a weaker response in the presence of NTD. Overall, these data provide a strong rationale for repositioning Ponatinib to dampen the SARS-CoV-2-induced cytokine storm and be immediately tested in the clinic. In summary, we discovered a previously unknown function of the NTD of the SARS-CoV-2 spike protein in promoting cytokine release in immune cells. We identified several new hostspecific kinases that are required for the SARS-CoV-2 spike protein-mediated release of cytokines and chemokines in monocytes. Our findings strongly suggest that simultaneous targeting of multiple host kinases involved in SARS-CoV-2 mediating cytokine storm yield more effective treatment options than the use of more selective agents. More specifically, our results suggest that an FDA-approved drug, Ponatinib, could represent a strong candidate for drug repurposing efforts aimed at providing an alternative, and timely treatment for COVID-19 patients exhibiting major, life-threatening symptoms. and PBMCs (right) upon treatment with fulllength S1 subunit at 1 µg/ml for 24 hr. (C) Changes in the expression of cytokines in THP1 macrophages upon treatment with different domains of S1 subunit at 1 µg/ml for 24 hr. (D) Measurement of cytokine release from healthy donor PBMCs treated with PBS or NTD at 1 µg/ml for 24 hr. (E) Effect of an anti-RBD antibody on S1 subunit stimulated changes in the expression of cytokines in PBMCs. Gene expression was measured by qPCR. Cytokine release in the conditioned media was measured by Luminex. Full-length S1 and S1 subunits are purified from HEK293 cells. Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. THP1 and Raw264.7 cells were obtained from American Type Culture Collection. Peripheral blood mononuclear cells (PBMCs) from healthy donors spanning various age groups were obtained from Bloodworks NW, Seattle, Washington. PBMCs and THP-1 cells were cultured in RPMI1640 media supplemented with 10% FBS, 1% P/S, 1 mM sodium pyruvate. Raw264.7 cells were maintained in Dulbecco's minimum essential medium supplemented with 10% FBS (Sigma) and 1% Penn Strep. All cell lines were grown at 37°C under 5% CO2, 95% ambient atmosphere. Ponatinib (Cat# S1490), dexamethasone (Cat# S1322) and baricitinib (Cat# S2851) were obtained from Selleck Chemicals. Recombinant purified full length S1 protein (Cat# 230- 2 emerging variants were obtained from Acro Biosystems (Cat # S1D-C52H9 and # S1D-C52H7). Cytokines were measured by Luminex multiplex assay. Samples and cytokine standards were incubated with Luminex microbeads (one unique bead population per cytokine) coated with cytokine-specific antibodies. Beads are washed then incubated 1 hour with biotinylated anticytokine antibodies, washed again then incubated 30 minutes with a phycoerythrin-streptavidin conjugate. After a final wash the assay is read on a Luminex 200 instrument, classifying each bead as to its cytokine-specificity and phycoerythrin fluorescence intensity. Phycoerythrin fluorescence of each bead will be proportional to the cytokine concentration in the samples or standards. A 5-parameter logistic standard curve is generated for each cytokine, with sample concentrations calculated from these curves. Kinase inhibitor screening was performed as described previously 2 . Briefly, 35 kinase inhibitors were tested for the effect on NTD-mediated cytokine release in PBMC. All inhibitors were tested at 500nM. Pooled PBMC from several donors were plated in 12-well plate (1X10 6 cell per well in 1mL). Kinase inhibitors or DMSO control was subsequently added to each well. Conditioned medium collected 24 hours post treatment was snap frozen for cytokine analysis. The effects of inhibitors as single agent on viability of PBMCs was measured using CellTiter-Glo assay (Promega, WI, USA) as described previously 3, 4 . Briefly, cells (5x10 3 in 100 ul culture medium) were seeded on a 96-well plate (Corning, NY, USA). Cells were then treated with various inhibitors at 500nM as single agent. After 24 hours, cells were incubated with CTG2.0 reagent for 5 min and total viability was measured by obtaining luminescent signal intensity. The quantified data was normalized to untreated control and plotted in Prism (Graphpad software, San Diego, CA, USA). All small interfering RNA (siRNA) targeting human kinases were obtained from Dharmacon (Thermo). siRNA's transfections in 12-well plate for expression and cytokine profiling was carried out using Lipofectamine RNAiMax (Invitrogen) according to manufacturer instructions. Total cellular RNA was isolated using an RNeasy Mini Kit (QIAGEN). mRNA expression changes in genes encoding for various cytokines wer determined using quantitative real-time PCR (qPCR). Briefly, 0.5-1 μg of total RNA was reverse transcribed into first-strand cDNA using an RT2 First Strand Kit (QIAGEN). The resultant cDNA was subjected to qPCR using human cytokine-specific primer (Realtimeprimers.com) and GAPDH (housekeeping control). The qPCR reaction was performed with an initial denaturation step of 10 min at 95 °C, followed by 15 s at 95 °C and 60 s at 58 °C for 40 cycles using Biorad CFX384 thermocycler (Biorad). The mRNA levels of genes encoding cytokine expression were normalized relative to the mean levels of the housekeeping gene and compared using the 2−ΔΔCt method as described previously 2 . Primersets to measure cytokine expression were obtained from Realtimeprimers.com. KiR models for NTD-mediated release of each cytokine in PBMCs were generated as previously described (Gujral et Leave-one-out cross validation (LOOCV) was used to select the optimal value for the penalty scaling factor λ. Models were computed for 11 evenly-spaced values of α (the relative weighting between LASSO and Ridge regularization) ranging from 0 to 1.0 inclusive. Kinases with positive coefficients in at least one of these models (with the exception of = , which always has non-zero coefficients for every kinase) were considered hits ( Figure S4A) . Model accuracy was assessed via the LOOCV error as well as the root-mean-squared error of the predictions for the tested inhibitors ( Figure S2 ). The development of the DeepKinX DNN models were achieved through the Keras and TensorFlow Deep Learning framework as described previously [5] [6] [7] . Briefly, a multi-phase Grid Search method was used to optimize the DNN hyperparameters (epochs, batch size, optimizer, weight initializer, activation function, hidden layer quantity and nodes per hidden layer) 8 Search is a commonly employed method of hyperparameter optimization that evaluates combinations of numerous hyperparameter values to identify the model characteristics resulting in the lowest error between observed and predicted migration. The error function that was used to compare numerous models was LOOCV (Leave-One-Out-Cross-Validation) MSE 9 Assuming a trained DeepKinX DNN model defined by and a dataset defined by [ , 1 , 2 , 3 , … ], the baseline error ( ) can be estimated, assuming a pre-defined cost function. For both DeepKinX-Fzd2 and DeepKinX-WT models, the cost function was defined as follows: The baseline error was subsequently calculated as defined below: to increase as the number of inputs decrease. To predict the effect of all 427 drugs of the original matrix, the final DeepKinX-Huh7 model was trained on the 44-drug training matrix. Keeping the weights and biases of the DeepKinX-Huh7 network constant, new kinase activity data for naïve drugs were inputted into the model for prediction. Further, the effect of combinations of drugs were also predicted by creating pseudo-activity matrices. Assuming two activity matrices for two different drugs The custom python scripts that implements KiDNN framework are available on GitHub: https://github.com/gujrallab/Covid-19. This repository also includes all associated files needed to execute the script and produce a sample model using the training dataset. R scripts for KiR modeling is available at https://github.com/FredHutch/KiRNet-Public Dataset 1. Drug screen data, and machine learning-based predicted kinases and kinase inhibitors Preventing COVID-19-induced pneumonia with anticytokine therapy THP-1 cells as a model for human monocytes Structural basis of receptor recognition by SARS-CoV-2 Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation Non-linear Deep Neural Network for Rapid and Accurate Prediction of Phenotypic Responses to Kinase Inhibitors Exploiting polypharmacology for drug target deconvolution Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles Baricitinib for COVID-19: a suitable treatment? The Lancet Infectious Diseases Tissue-aware data integration approach for the inference of pathway interactions in metazoan organisms A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis Exploiting polypharmacology for drug target deconvolution Non-linear Deep Neural Network for Rapid and Accurate Prediction of Phenotypic Responses to Kinase Inhibitors Non-linear Deep Neural Network for Rapid and Accurate Prediction of Phenotypic Responses to Kinase Inhibitors Tensorflow: Large-scale machine learning on heterogeneous distributed systems Advances in neural information processing systems Model selection via multifold cross validation. The annals of statistics This work was supported by grants from the Fred Hutch COVID19 Pilot Fund and Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685. We thank Dr. Milka Kostic for her helpful comments and suggestions for the manuscript.